PLEKHB2

Across TCGA pan-cancer cohorts, PLEKHB2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLEKHB2 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PLEKHB2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PLEKHB2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

UCEC, PDAC, and LUAD are the cancer types where PLEKHB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.815	.003	22	view →
PDAC	OS	Tertile	All	0.765	0.330	.001	14	view →
LUAD	DFS	Tertile	III,IV	0.321	0.771	.008	12	view →
GBM	OS	Tertile	All	0.419	0.667	.008	4	view →
CCRCC	DFS	Tertile	III,IV	0.396	0.659	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLEKHB2–UCEC (DFS)

Open the UCEC breakdown →